Sarepta Therapeutics, Inc.
NASDAQSarepta Therapeutics just delivered one of the most dramatic earnings beats in its recent history — and yet the short position barely flinched. Q1 adjusted EPS of $3.16 demolished the $0.99 consensus estimate by more than 200%. Revenue of $730.8 million shredded the $474.2 million forecast. ELEVIDYS, the company's gene therapy for Duchenne muscular dystrophy, is clearly performing…
Snapshot as of 7 May 2026
Sarepta Therapeutics just delivered one of the most dramatic earnings beats in its recent history — and yet the short position barely flinched. Q1 adjusted EPS of $3.16 demolished the $0.99 consensus estimate by more…
Sarepta Therapeutics reports Q1 2026 results on May 6, and the setup heading in is tense: short interest is running near its highest level in months, a fresh spike in options defensiveness just appeared, and the most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SRPT — free to start on ORTEX.
Sign up for free →Open SRPT on ORTEX